EV/EBIT
Enterprise Value to EBIT

-13.7
Current
-12.5
Median
15.9
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-13.7
=
Enterprise Value
225.8m EUR
/
EBIT
-25.8m CAD
Market Cap EV/EBIT
CA
SNDL Inc
F:VY4
295.9m EUR -13.7
US
Eli Lilly and Co
NYSE:LLY
677.8B USD 36
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
US
Johnson & Johnson
NYSE:JNJ
367.1B USD 16.2
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 14.9
CH
Roche Holding AG
SIX:ROG
205.4B CHF 10.9
CH
Novartis AG
SIX:NOVN
182.3B CHF 13.5
UK
AstraZeneca PLC
LSE:AZN
161.1B GBP 197
US
Merck & Co Inc
NYSE:MRK
195.9B USD 10.2
IE
Endo International PLC
LSE:0Y5F
163.5B USD 655.3
FR
Sanofi SA
PAR:SAN
115.6B EUR 5.9
EBIT Growth EV/EBIT to Growth
CA
SNDL Inc
F:VY4
Average EV/EBIT: 1 866.2
Negative Multiple: -13.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.2
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
14.9
14%
1.1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
13.5
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197
21%
9.4
US
Merck & Co Inc
NYSE:MRK
10.2
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
FR
Sanofi SA
PAR:SAN
5.9
14%
0.4

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-178.4
2-Years Forward
EV/EBIT
-64.1
3-Years Forward
EV/EBIT
55.9